Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

18.45 +0.01 (+0.05%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries ADR

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
24 25 Next >
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
From Teva Pharmaceutical Industries Limited
Via Business Wire
7 Core Stocks to Build a Solid Portfolio Around
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation. 
Via InvestorPlace
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
By Julian Richard, Benzinga 
Via TheNewswire.com
Why Teva Pharmaceutical Stock Is Sliding Today
Investors were disappointed with the drugmaker's 2023 outlook. 
Via The Motley Fool
Teva Pharmaceutical Stock Dives On Fourth-Quarter Miss, Light 2023 Guidance
The company missed fourth-quarter estimates and issued light guidance. 
Via Investor's Business Daily
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome 
Via News Direct
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or... 
Via Benzinga
Teva to Present at the Barclays Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Better Generics Pharmaceutical Stock: Teva or Viatris?
Both have plans to return to growth. 
Via The Motley Fool
Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
From Teva Pharmaceutical Industries Limited
Via Business Wire
7 Smart Stock Picks for Cautious Investors
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors. 
Via InvestorPlace
Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
From Teva Pharmaceutical Industries Limited
Via Business Wire
Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday
With US futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap?
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug
Axsome Therapeutics (AXSM) stock is taking a beating on Monday as rival Teva Pharmaceutical (TEVA) prepares a generic depression drug. 
Via InvestorPlace
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
The company only just gained approval for its depression drug in August. 
Via Investor's Business Daily
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharmaceutical Industries (TEVA) Q4 2022 Earnings Call Transcript
TEVA earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Teva Pharma Posts Lower Q4 Earnings, FY23 Outlook Within Expectations
Via Benzinga
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026
These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite. 
Via The Motley Fool
The 7 Best Growth Stocks to Buy for February 2023
Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors. 
Via InvestorPlace
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
Things aren't as bad as they might seem. 
Via The Motley Fool
6 Great Stocks to Buy in 2023 and Hold Forever
I own all six great businesses and don't plan to sell a single share. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.